All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
Janus kinase (JAK) proteins promote survival and proliferation of cells by activation of the STAT signaling pathway and are induced by hematopoietic cytokine and growth factor receptor activation. JAK inhibitors, such as ruxolitinib, filgotinib, and tofacitinib, have shown clinical efficacy.